Exiqon A/S' share capital and total number of voting rights
Pursuant to Section 6 of executive order no. 226 of 15 March 2007 about issuers'
disclosure obligations, it is hereby announced that Exiqon A/S' entire share
capital on 28 December 2007 is DKK 24,441,064, nominal value, divided into
shares of DKK 1.00, nominal value, each. Every share of DKK 1.00, nominal value,
carries one vote. The total number of voting rights is 24,441,064.
For additional information please contact
Lars Kongsbak, CEO, tel +45 4566 0450 or +45 4090 2101
Hans Henrik Chrois Christensen, CFO +45 4565 0953 or +45 4090 2131
About Exiqon
Exiqon is a leading provider of high-value gene expression analysis products for
the life sciences, research and drug discovery industries. Exiqon's rapidly
growing product offerings integrate innovative chemistries with web-based
software tools to help scientists achieve rapid and reliable results. Exiqon
markets its products directly on www.exiqon.com or through distributors in Asia
and parts of EU, as well as through its dedicated sales force in the US and
Europe. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and
in Boston, USA. Please visit our web-site at www.exiqon.com.
DISCLAIMER
Forward-looking statements
This announcement contains forward-looking statements regarding the Company's
future development and financial performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge, are reasonable and
well-founded at this time, but which may prove to be erroneous. The Company's
operations are characterised by the fact that its actual results may deviate
significantly from those described herein as anticipated, believed, estimated or
expected.